Stieglitz, Elliot <br/><br/>
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.  [electronic resource] 

 -  Pediatric blood & cancer  Apr 2015 
 - 629-36 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.25342  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Child<br/>Child, Preschool<br/>Cytarabine--administration & dosage<br/>Disease-Free Survival<br/>Enzyme Inhibitors--administration & dosage<br/>Farnesyl-Diphosphate Farnesyltransferase--antagonists & inhibitors<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Infant<br/>Isotretinoin--administration & dosage<br/>Leukemia, Myelomonocytic, Juvenile--drug therapy<br/>Male<br/>Middle Aged<br/>Quinolones--administration & dosage<br/>Survival Rate<br/>Vidarabine--administration & dosage